Becton Dickinson Gestione

Gestione criteri di controllo 1/4

Becton Dickinson Il CEO è Tom Polen, nominato in Apr2017, e ha un mandato di 5.42 anni. la retribuzione annua totale è $ 14.19M, composta da 8.6% di stipendio e 91.4% di bonus, comprese azioni e opzioni aziendali. possiede direttamente 0.01% delle azioni della società, per un valore di CHF 6.63M. La durata media del mandato del team dirigenziale e del consiglio di amministrazione è rispettivamente 1.2 anni e 5.8 anni.

Informazioni chiave

Tom Polen

Amministratore delegato

US$14.2m

Compenso totale

Percentuale dello stipendio del CEO	8.6%
Mandato del CEO	5.4yrs
Proprietà del CEO	0.01%
Durata media del management	1.2yrs
Durata media del Consiglio di amministrazione	5.8yrs

Aggiornamenti recenti sulla gestione

Recent updates

Analisi delle retribuzioni degli amministratori delegati

Come è cambiata la remunerazione di Tom Polen rispetto agli utili di Becton Dickinson?
Data	Compenso totale	Stipendio	Guadagni aziendali
Jun 30 2022	n/a	n/a	US$2b
Mar 31 2022	n/a	n/a	US$2b
Dec 31 2021	n/a	n/a	US$2b
Sep 30 2021	US$14m	US$1m	US$2b
Jun 30 2021	n/a	n/a	US$1b
Mar 31 2021	n/a	n/a	US$1b
Dec 31 2020	n/a	n/a	US$2b
Sep 30 2020	US$12m	US$952k	US$767m
Jun 30 2020	n/a	n/a	US$786m
Mar 31 2020	n/a	n/a	US$923m
Dec 31 2019	n/a	n/a	US$760m
Sep 30 2019	US$6m	US$900k	US$1b
Jun 30 2019	n/a	n/a	US$784m
Mar 31 2019	n/a	n/a	US$926m
Dec 31 2018	n/a	n/a	US$894m
Sep 30 2018	US$6m	US$850k	US$159m
Jun 30 2018	n/a	n/a	US$621m
Mar 31 2018	n/a	n/a	-US$99m
Dec 31 2017	n/a	n/a	US$294m
Sep 30 2017	US$4m	US$761k	US$1b
Jun 30 2017	n/a	n/a	US$759m
Mar 31 2017	n/a	n/a	US$1b
Dec 31 2016	n/a	n/a	US$1b
Sep 30 2016	US$3m	US$651k	US$976m

Compensazione vs Mercato: La retribuzione totale di Tom ($USD 14.19M ) è superiore alla media delle aziende di dimensioni simili nel mercato Swiss ($USD 4.75M ).

Compensazione vs guadagni: La retribuzione di Tom è aumentata di oltre il 20% nell'ultimo anno.

AMMINISTRATORE DELEGATO

Tom Polen (49 yo)

5.4yrs

Mandato

US$14,189,333

Compensazione

Mr. Thomas E. Polen, Jr., also known as Tom, serves as Chief Executive Officer and Director at Becton, Dickinson and Company since January 28, 2020. Mr. Polen has been President of Becton, Dickinson and Co...

Gruppo dirigente

Nome	Posizione	Mandato	Compensazione	Proprietà
Thomas Polen	President	5.4yrs	US$14.19m	0.010% CHF 6.6m
Christopher DelOrefice	Executive VP & CFO	less than a year	US$1.61m	Nessun dato
Samrat Khichi	Executive VP of Corporate Development	4.8yrs	US$3.53m	0.0021% CHF 1.4m
Thomas Spoerel	Senior VP	2.9yrs	Nessun dato	0.00054% CHF 353.3k
Elizabeth McCombs	Executive VP & Chief Technology Officer	1.4yrs	Nessun dato	Nessun dato
Joseph Smith	Senior VP	less than a year	Nessun dato	Nessun dato
Denise Fleming	Executive VP of Technology & Global Services and Chief Information Officer	less than a year	Nessun dato	Nessun dato
Francesca DeMartino	Senior VP & Head of Investor Relations	less than a year	Nessun dato	Nessun dato
Michelle Quinn	Senior VP and Chief Ethics & Compliance Officer	no data	Nessun dato	Nessun dato
Troy Kirkpatrick	Vice President of Public Relations	no data	Nessun dato	Nessun dato
Antoine Ezell	Executive VP	2.7yrs	Nessun dato	0.0026% CHF 1.7m
Ginny Blocki	Senior VP of Global Marketing & Product Management	less than a year	Nessun dato	Nessun dato

1.2yrs

Durata media

50yo

Età media

Gestione esperta: Il team dirigenziale di 000912061 non è considerato esperto (durata media 1.2 anni), il che suggerisce un nuovo team.

Membri del Consiglio di amministrazione

Nome	Posizione	Mandato	Compensazione	Proprietà
Thomas Polen	President	2.7yrs	US$14.19m	0.010% CHF 6.6m
Joseph Smith	Senior VP	less than a year	Nessun dato	Nessun dato
John DeFord	Co-Chair of Scientific Advisory Board	1.3yrs	Nessun dato	Nessun dato
Marshall Larsen	Independent Lead Director	15yrs	US$386.17k	0.0083% CHF 5.5m
Robert Eckert	Independent Director	6yrs	US$321.17k	0.0022% CHF 1.4m
Timothy Ring	Independent Director	5.7yrs	US$326.17k	0.028% CHF 18.4m
Jeffrey Henderson	Independent Director	4.1yrs	US$326.17k	0.0013% CHF 863.7k
Christopher Ian Jones	Independent Director	12.2yrs	US$351.17k	0.0066% CHF 4.3m
Bertram Scott	Independent Director	20yrs	US$346.17k	0.011% CHF 7.3m
Catherine Burzik	Independent Director	9.7yrs	US$351.17k	0.0044% CHF 2.9m
Claire Fraser-Liggett	Member of Scientific Advisory Board & Independent Director	15.8yrs	US$346.17k	0.0076% CHF 4.9m
Carrie Byington	Independent Director	less than a year	Nessun dato	0% CHF 0

5.8yrs

Durata media

64yo

Età media

Consiglio di amministrazione esperto: I membri del consiglio di amministrazione di 000912061 sono considerati esperti (durata media dell'incarico 5.8 anni).

Becton Dickinson Gestione

Gestione criteri di controllo 1/4

Informazioni chiave

Aggiornamenti recenti sulla gestione

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

Becton, Dickinson and Company Announces Executive Changes

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Recent updates

Becton, Dickinson and Company Has Declares A Quarterly Dividend, Payable on December 31, 2024

Becton, Dickinson and Company Launches Enhanced Intraosseous System, Enabling Vascular Access in Seconds for Critical Care Situations

Becton, Dickinson and Company Announces New Robotics Solution to Automate, Standardize Single-Cell Research

Becton, Dickinson and Company to Report Q4, 2024 Results on Nov 07, 2024

Becton, Dickinson and Company Reaches Multi-Year Settlement in Hernia Mesh Lawsuits

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW).

BD Names Michael Feld as President of Life Sciences Segment, Effective August 20, 2024

Becton, Dickinson and Company Updates Earnings Guidance for the Year 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2024

Becton, Dickinson and Company to Report Q3, 2024 Results on Aug 01, 2024

BD (Becton, Dickinson and Company) Announces the Commercial Launch of a New Single-Cell Research Tool

Becton, Dickinson and Company (NYSE:BDX) entered into an agreement to acquire Critical Care Product Group of Edwards Lifesciences Corporation (NYSE : EW) for $4.2 billion.

Becton, Dickinson and Company Revises Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 28, 2024

Becton, Dickinson and Company (NYSE:BDX) acquired FlowJo LLC.

Becton, Dickinson and Company to Report Q2, 2024 Results on May 02, 2024

Becton, Dickinson and Company Initiates International Study to Expand Treatment Options for Patients with Peripheral Arterial Disease

Dave Hickey Retires as Executive Vice President and President of the Life Sciences Segment for BD, Effective from July 1, 2024

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year of 2024

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on March 29, 2024

Becton, Dickinson and Company to Report Q1, 2024 Results on Feb 01, 2024

Becton, Dickinson and Company, Annual General Meeting, Jan 23, 2024

BD Receives FDA 510(K) Clearance for Potentially Transformative Fingertip Blood Collection Device

BD Launches Advanced Vascular Access Ultrasound System Designed to Improve Clinician Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Increases Quarterly Dividend, Payable on December 29, 2023

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2024

Becton, Dickinson and Company Announces Launch of Next-Generation Needle-Free Blood Draw Technology

BD Names Greg Rodetis as Senior Vice President of Investor Relations

Becton, Dickinson and Company to Report Q4, 2023 Results on Nov 09, 2023

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

Becton, Dickinson and Company Elects Joanne Waldstreicher to the Board and as Member of the Corporate Governance and Nominating Committee and the Quality and Regulatory Committee of the Board

Becton, Dickinson and Company Receives FDA 510(k) Clearance for Updated BD Alaris™? Infusion System

Becton, Dickinson and Company to Report Q3, 2023 Results on Aug 03, 2023

STERIS Corporation agreed to acquire Surgical Instrumentation platform from Becton, Dickinson and Company for $540 million.

Becton, Dickinson and Company Raises Earnings Guidance for the Fiscal Year 2023

BD Receives FDA Emergency Use Authorization for COVID-19, Influenza A/B, RSV Combination Test

Becton, Dickinson and Company Introduces High-Throughput Single-Cell Multiomics Platform to Expand Scope of Scientific Discovery

Becton, Dickinson and Company Provides Earnings Guidance for the Year 2023

BD (Becton, Dickinson and Company) Declares Quarterly Dividend, Payable on March 31, 2023

Becton, Dickinson and Company Introduces Fully Automated Robotic Track System for Microbiology Labs

Becton, Dickinson and Company and CerTest Biotec Announce Emergency Use Authorization from U.S. Food and Drug Administration for Molecular Polymerase Chain Reaction Assay for Mpox Virus Detection

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company to Report Q1, 2023 Results on Feb 02, 2023

Becton, Dickinson and Company, Annual General Meeting, Jan 24, 2023

Becton, Dickinson and Company Board Increases Quarterly Dividend, Payable on December 30, 2022

Becton, Dickinson and Company to Report Fiscal Year 2022 Results on Nov 10, 2022

Becton, Dickinson and Company Appoints Eric Borin President of Medication Delivery Solutions

BD Launches Cloud Software Solution to Streamline Flow Cytometry Research

BD, Certest Biotec Announce US Commercial Launch of Monkeypox Assay

Becton, Dickinson and Company Launches Next Generation Prefillable Vaccine Syringe Designed for Reliability, Efficiency

Becton, Dickinson and Company Announces Executive Changes

Becton, Dickinson and Company Raises Revenue Guidance for the Full-Year 2022

Becton, Dickinson and Company (NYSE:BDX) acquired MedKeeper from Grifols, S.A. (BME:GRF) for $93 million.

Becton, Dickinson and Company Certest Biotec Announce Commercial Launch of Monkeypox Test

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on September 30, 2022

Becton, Dickinson and Company (NYSE:BDX) completed the acquisition of Parata Systems, LLC from Frazier Healthcare Partners.

Becton, Dickinson and Company to Report Q3, 2022 Results on Aug 04, 2022

Becton, Dickinson and Company Announces Management Changes

Becton, Dickinson and Company Launches Combination Test for COVID-19, Influenza A/B and Respiratory Syncytial Virus

BD Announces Voluntary Recall on Intraosseous Products

Becton, Dickinson and Company Appoints Simon Campion as Executive Vice President and President of the Medical Segment, Effective July 1, 2022

Becton, Dickinson and Company (NYSE:BDX) (BD) entered into a definitive agreement to acquire Parata Systems, LLC from Frazier Healthcare Partners for $1.5 billion.

Becton, Dickinson and Company Launches Fully Automated, High-Throughput Infectious Disease Molecular Diagnostic Platform in the U.S

Becton, Dickinson and Company Provides Earnings Guidance for the Fiscal Year 2022

Becton, Dickinson and Company Declares Quarterly Dividend, Payable on June 30, 2022

New Becton, Dickinson and Company Reagents Enable Researchers to Break Through Resolution Boundaries in Flow Cytometry

Becton, Dickinson and Company to Report Q2, 2022 Results on May 05, 2022

Becton, Dickinson and Company Announces Management Changes